Vor Biopharma (NASDAQ:VOR) Raised to Hold at Zacks Research

Zacks Research upgraded shares of Vor Biopharma (NASDAQ:VOR) from a strong sell rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

Several other analysts also recently weighed in on VOR. Wall Street Zen downgraded Vor Biopharma to a “strong sell” rating in a research report on Saturday, June 28th. HC Wainwright upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Vor Biopharma Trading Up 0.8%

Shares of NASDAQ VOR opened at $1.82 on Wednesday. The stock has a market cap of $229.92 million, a PE ratio of -0.13 and a beta of 2.05. Vor Biopharma has a 1-year low of $0.13 and a 1-year high of $3.29. The firm’s 50-day moving average price is $2.12.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($1.61).

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.